Antitumor and immunomodulatory activity of resveratrol on experimentally implanted tumor of H22 in Balb/c mice.
OBJECTIVE
To study the antitumor and immunomodulatory activity of resveratrol on experimentally implanted tumor of H22 in Balb/c mice.


METHODS
The cytotoxicity of peritoneal macrophages (Mphi) against H22 cells was measured by the radioactivity of ((3)H)TdR assay, mice with H22 tumor were injected with different concentrations of resveratrol, and the inhibitory rates were calculated and IgG contents were determined by single immunodiffusion method. the plaque forming cell (PFC) was measured by improved Cunningham method, the levels of serum tumor necrosis factor-alpha (TNF-alpha) were measured by cytotoxic assay against L929 cells.


RESULTS
Resveratrol 2.5 mg x L(-1), 5.0 mg x L(-1), 10.0 mg x L(-1), 20.0 mg x L(-1) (E:T=10:1, 20:1) promoted the cytotoxicity of Mphi against H22 cells. Resveratrol ip 500 mg x kg(-1), 1 000 mg x kg(-1) and 1,500 mg x kg(-1) could curb the growth of the implanted tumor of H22 in mice. The inhibitory rates were 31.5 %, 45.6 % and 48.7 %, respectively (P<0.05), which could raise the level of serum IgG and PFC response to sheep red blood cell. Resveratrol 1,000 mg x kg(-1) and 1,500 mg x kg(-1) and BCG 200 mg x kg(-1) ip could increase the production of serum TNF-alpha in mice H22 tumor. However, the effect of resveratrol was insignificant (P>0.05).


CONCLUSIONS
Resveratrol could inhibit the growth of H22 tumor in Balb/c mice. The antitumor effect of resveratrol might be related to directly inhibiting the growth of H22 cells and indirectly inhibiting its potential effect on nonspecific host immunomodulatory activity.
Liu
Hong-Shan
HS
Department of Hepatobiliary Surgery, First Affiliated Hospital, Xi'an Jiaotong University, Xi'an 710061, Shaanxi Province, China. doctorliuqi@ yahoo.com.cn
Pan
Cheng-En
CE
Yang
Wei
W
Liu
Xue-Min
XM
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000921:Antibody-Producing Cells / Q000187:drug effects; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000276:immunology; D004912:Erythrocytes; D007074:Immunoglobulin G / Q000097:blood; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy* / Q000276:immunology; D017737:Macrophages, Peritoneal / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D000077185:Resveratrol; D012756:Sheep; D013267:Stilbenes / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000276:Adjuvants, Immunologic; D000972:Antineoplastic Agents, Phytogenic; D007074:Immunoglobulin G; D013267:Stilbenes; D014409:Tumor Necrosis Factor-alpha; D000077185:Resveratrol